Emergent BioSolutions (EBS) Misses Q2 EPS by 43c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.28 +1.22%
EPS Growth %: -31.3%
Financial Fact:
Product sales: 96.7M
Today's EPS Names:
EPAC, SAR, KRUS, More
EPS Growth %: -31.3%
Financial Fact:
Product sales: 96.7M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($1.06), $0.43 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $337.9 million versus the consensus estimate of $217.03 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
- Syra Health names Dr. Cori McMahon as fractional chief medical officer
- DA Davidson Reiterates Neutral Rating on Fastenal (FAST), Says Would Buy on 'Any Meaningful Retrenchment'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
